Real-life results of tremelimumab, durvalumab and chemotherapy in advanced non-squamous lung cancer
Follows adults with advanced non-squamous lung cancer treated with tremelimumab, durvalumab and chemotherapy.
Plain-language title generated from the registry record
Registry title: NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Key facts
- Where
- Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt, Georgsmarienhütte, Gera, Goslar, Greifswald, Halle-Dolau, Hanover, Herne, Hösbach, Koblenz, Koln-Mehrheim, Mainz, Marburg, Münnerstadt, Neuss, Offenbach, Querfurt, Ravensburg, Rüsselsheim am Main, Treuenbrietzen, Ulm, Wiesbaden, and Zwickau, GermanySee the 30 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-squamous metastatic non-small cell lung cancer who are about to start first-line treatment with tremelimumab, durvalumab and platinum chemotherapy (TDC). It is a non-interventional study in Germany.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Non-squamous metastatic non-small cell lung cancer, confirmed by tissue or cell tests. Large cell neuroendocrine carcinoma can join if the treating doctor considers it NSCLC-like.
- Earlier treatment
- The decision has been made to start first-line treatment with TDC as approved. No earlier treatment is described.
- Biomarker or test result
- No sensitizing EGFR mutations and no ALK changes. Tests of KRAS, STK11, KEAP1 and TP53 genes, TTF-1 and PD-L1 have been started.
Main reasons for not taking part
- Taking part in an interventional clinical trial now
- Contraindications listed in the product information (SmPC)
- Any active tumor other than metastatic NSCLC, if the investigator finds it likely to affect the outlook or care of the lung cancer
- Mixed adenocarcinoma and squamous cell tumor
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Source: NCT06494540, who can take part
Where in Germany
- Bad HomburgHospital not named in the registryTaking people
- BerlinHospital not named in the registryTaking people
- BremenHospital not named in the registryTaking people
- CelleHospital not named in the registryNo longer taking part
- ChemnitzHospital not named in the registryTaking people
- CologneHospital not named in the registryTaking people
- DeggendorfHospital not named in the registryTaking people
- FrankfurtHospital not named in the registryTaking people
- GeorgsmarienhütteHospital not named in the registryTaking people
- GeraHospital not named in the registryNo longer taking part
- GoslarHospital not named in the registryTaking people
- GreifswaldHospital not named in the registryTaking people
- Halle-DolauHospital not named in the registryTaking people
- HanoverHospital not named in the registryTaking people
- HerneHospital not named in the registryTaking people
- HösbachHospital not named in the registryTaking people
- KoblenzHospital not named in the registryTaking people
- Koln-MehrheimHospital not named in the registryTaking people
- MainzHospital not named in the registryTaking people
- MarburgHospital not named in the registryTaking people
- MünnerstadtHospital not named in the registryTaking people
- NeussHospital not named in the registryTaking people
- OffenbachHospital not named in the registryTaking people
- QuerfurtHospital not named in the registryTaking people
- RavensburgHospital not named in the registryTaking people
- Rüsselsheim am MainHospital not named in the registryNo longer taking part
- TreuenbrietzenHospital not named in the registryTaking people
- UlmHospital not named in the registryTaking people
- WiesbadenHospital not named in the registryTaking people
- ZwickauHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06494540
- Record updated
- 28 September 2026
- Original description
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl. large cell neuroendocrine carcinoma (LCNEC) if considered NSCLC-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (TDC) according to marketing authorization was scheduled. The study aims to describe the effectiveness with respect to mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/threonine kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), and Tumor protein p53 (TP53) as well as expression of Thyroid transcription factor 1 (TTF-1) and Programmed death-ligand 1 (PD-L1) in routine clinical practice. The generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for NSQ mNSCLC in distinct subgroups with a high medical need.Read full original descriptionShow less
Prospective Non-interventional Study (NIS) to Examine the Effectiveness of Tremelimumab + Durvalumab + Platinum Chemotherapy (TDC) in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl. large cell neuroendocrine carcinoma (LCNEC) if considered NSCLC-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (TDC) according to marketing authorization was scheduled. The study aims to describe the effectiveness with respect to mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/threonine kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), and Tumor protein p53 (TP53) as well as expression of Thyroid transcription factor 1 (TTF-1) and Programmed death-ligand 1 (PD-L1) in routine clinical practice. The generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for NSQ mNSCLC in distinct subgroups with a high medical need.
Inclusion: Aged ≥ 18 years; Decision to start first-line (1L) treatment with TDC according to the current SmPCs; Histologically or cytologically confirmed diagnosis of NSQ mNSCLC (incl. LCNEC if considered NSCLC-like by the treating physician); No sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) alterations; Molecular Next Generation Sequencing (NGS) panel as per institutional standard has been initiated (including the following genes: KRAS, STK11, KEAP1, and TP53); TTF-1 expression analysis has been initiated; PD-L1 expression analysis has been initiated; Women of childbearing potential must use effective contraception during treatment with durvalumab and for at least 3 months after the last dose of durvalumab; Ability to understand the study concept; Provision of signed informed consent form in accordance with applicable local provisions.
Exclusion: Current participation in interventional clinical trials; Contraindications according to current SmPCs; Any active tumor other than metastatic NSCLC*; Mixed histology NSCLC with both adenocarcinoma and squamous cell carcinoma components (adenosquamous carcinoma or any mixed NSQ- squamous tumor), regardless of the predominant component; determined by investigator as likely to influence the prognosis or management of mNSCLC.